Faeth Therapeutics

Faeth Therapeutics is an oncology-focused biotech developing a data-driven platform to match tumor genotypes with precision metabolic interventions. The company's core hypothesis is that modulating nutrient availability can fundamentally alter the tumor microenvironment and enhance the efficacy of standard cancer treatments. In early 2025, Faeth was acquired by Sensei Biotherapeutics, indicating a strategic consolidation to advance its metabolic therapy platform. The company operates as a private, pre-revenue entity advancing its programs through preclinical and early clinical development.

Data-driven discovery platform that matches tumor genotypes with precision metabolic optimization regimens, combining therapeutic targets with specific nutrient interventions to impair tumor growth.

Faeth operates in the emerging field of cancer metabolism, competing with other biotechs and academic centers exploring dietary restrictions, ketogenic diets, and specific enzyme inhibitors. Its differentiation lies in its genotype-matched, precision platform and its new integration with an immuno-oncology company's pipeline.